83 results about "Barr virus" patented technology

Disclosed is a non-invasive method for diagnosis, prognosis or monitoring of Epstein-Barr virus (EBV)-associated cancer by detecting and/or quantifying EBV associated nucleic acid fragments in a urine sample from an individual. Kits for diagnosis, prognosis or monitoring of cancer are also disclosed.

The present invention provides cytotoxic Epstein-Barr virus (EBV) T-cell epitopes derived from EBV structural antigens. Preferred epitopes include YLLEMLWRL (SEQ ID NO:1), YFLEILWGL (SEQ ID NO:32), YLLEILWRL (SEQ ID NO:33), YLQQNWWTL (SEQ ID NO:6), LLLALLFWL (SEQ ID NO:2), LLVDLLWLL (SEQ ID NO:3), LLLIALWNL (SEQ ID NO:4), WLLLFLAIL (SEQ ID NO:5), TLLVDLLWL (SEQ ID NO:7), LLWLLLFLA (SEQ ID NO:8), ILLIIALYL (SEQ ID NO:9), VLFIFGCLL (SEQ ID NO:10), RLGATIWQL (SEQ ID NO:11), ILYFIAFAL (SEQ ID NO:15), SLVIVTTFV (SEQ ID NO:17), LMIIPLINV (SEQ ID NO:20), TLFIGSHVV (SEQ ID NO:24), LIPETVPYI (SEQ ID NO:26), VLQWASLAV (SEQ ID NO:27) and QLTPHTKAV (SEQ ID NO:29). The present invention also provides methods of treating or preventing EBV infection in subjects which involve administration of EBV cytotoxic T-cell epitopes.

The invention belongs to the field of medicines and particularly relates to a new application of an iridoid glycoside compound, genipin-1-[beta]-D-gentiobioside, and a composition composed by compounding the genipin-1-[beta]-Dgentiobioside with other components as effective components for preparing antiviral drugs, antibacterial drugs, fever alleviating drugs, inflammation resistant drugs and anti-oxidizing drugs. The iridoid glycoside compound and the composition can be used for treating acute respiratory infection, flu, pneumonia, viral hepatitis type B, herpes zoster, herpes viral keratitis, viral myocarditis, Epstein-Barr virus infection, retrovirus infectious diseases and bacterial infectious diseases.

The present invention presents a method of preventing vertical transmission of an infectious disease comprising: (a) applying a photosensitizing composition to host tissues of birth canal of a mother during the intrapartum period; and (b) applying light to the host tissues after the step (a) at a wavelength absorbed by the photosensitizing composition so as to inhibit or eliminate infectious disease microorganisms that come into contact with the host tissues. The infectious disease may be caused by human immunodeficiency virus type 1, hepatitis B virus, hepatitis C virus, Group B Streptococcus, cytomegalovirus, Listeria monocytogenes, Chiamydia trachomatis, Escherichia coli, herpes simplex virus, Epstein-Barr virus, Toxoplasma gondii, human papilloma virus, and Candida.

The present invention relates to the identification of a subunit vaccine to prevent or treat infection of Epstein Barr Virus. In particular, EBNA-1 was identified as a vaccine antigen. In a specific embodiment, a purified protein corresponding to EBNA-1 elicited a strong CD4⁺ T cell response. The responsive CD4⁺ T cell are primarily T_H1 in function. EBNA-1 is an attractive candidate for a protective vaccine against EBV, and for immunotherapy of EBV infection and neoplasms, particularly with dendritic cells charged with EBNA-1.

The invention provides a herpes virus EBV (Epstein-Barr Virus) detection kit. The kit comprises a nucleic acid releasing agent and PCR (polymerase chain reaction) reaction solution, wherein the nucleic acid releasing agent comprises 0.01-0.5 mM/L of surfactin, 20-300 mM/L of potassium chloride, 0.01-2% of sodium dodecyl sulphate and 0.05-1% of ethanol; and the PCR reaction solution comprises an upstream primer and a downstream primer used for target polynucleotide amplification, and a probe used for target polynucleotide detection. The detection result of the method for releasing nucleic acid by the nucleic acid releasing agent in the kit disclosed by the invention has no obvious difference with the detection result of a boiling method, a strong protein denaturing agent is used during nucleic acid extraction in the kit disclosed by the invention for rapidly breaking the coat protein structure of a pathogen and releasing the nucleic acid of the pathogen, and release and extraction for DNA (deoxyribonucleic acid) can be rapidly finished without heating; the sensitivity of the EBV detection of the kit disclosed by the invention can achieve 400 copies/ml, and the quantitative linear range is 400-4.00E+09 copies/ml; by applying the kit, rapid and accurate detection can be performed on EBV-DNA in the unknown samples of blood plasma, throat swab, peripheral blood and the like, and reliable experimental basis is provided for diagnosing EBV infection.

The invention relates to a kit for quantitative detection of an Epstein-Barr virus (EBV) nucleic acid by using a fluorescent polymerase chain reaction (PCR) technology. A pair of primers is used for amplifying an EBV specific nucleic acid sequence and EBVDNA is quantitatively detected through a fluorescence probe and meanwhile, an internal reference DNA is detected by using a human endogenous gene specificity primer and the fluorescence probe. By adopting the kit, existence of the EBV and internal reference nucleic acid is simultaneously detected by a single-tube double-wavelength fluorescent PCR technology, the EBVDNA in whole blood, plasma and a nasopharyngeal secretion sample can be quantitatively detected, and the whether a PCR inhibitor or template loss caused by a misoperation in detection exists in the sample is judged by the detection result of the internal reference nucleic acid. Thus, the kit is simple, convenient and fast in operation, can provide sensitive and accurate quantitative result, and can be widely applied to quantitative detection of clinical EBV virus infection.

The present invention relates to a vaccine for the treatment or prevention of an EBV-associated disease in a subject, wherein said vaccine comprises a synthetic polypeptide comprising a plurality of different segments of at least one parent EBV polypeptide, and wherein the segments are linked together in a different relationship relative to their linkage in the at least one parent EBV polypeptide.

The invention discloses a molecular target hsa-miR203 for diagnosing and treating nasopharyngeal cancer related with Epstein-Barr virus (EBV) infection and application thereof. The microRNA can accurately reflect the conditions of retention and loss of EBV viruses in cells and tissues, and further can be used for diagnosing the nasopharyngeal cancer related with the EBV infection; and meanwhile, target genes E2F3, CCNG1 and the like controlled by the hsa-miR203 obviously inhibit the proliferation and conversion capacities of the cells, so the hsa-miR203 can be used for treating the nasopharyngeal cancer related with the EBV infection. Therefore, the hsa-miR203 has important scientific research theory and clinical application value, and provides new clue and proof for diagnosis, treatment or prognosis of EBV related tumors.

The invention discloses a treble real-time fluorescence quantitative polymerase chain reaction (PCR) method for simultaneously detecting an epstein-barr virus (EBV), a polyma virus (BKV) and a cytomegaloviruses (CMV) of people and a kit, which belong to medical molecular biological detection techniques. Three sets of primers and probes of the three viruses, which are designed by self, are adoptedto simultaneously detect a specimen to be detected. Experiments show that through adopting the three sets of probes and primers to simultaneously amplify a template to be detected or a manually-configured verification standard substance, the stocks of the three viruses in the specimen can be reflected peculiarly and correctly, and the three viruses cannot interfere with one another.

The invention relates to a quantitative fluorescent multiplex PCR test kit for Epstein-Barr virus, and the kit comprises the following reagents: a, specific primer pairs for amplifying mutations of key target genes in the Epstein-Barr virus; and b, specific probes for the mutations of key target genes in the Epstein-Barr virus, wherein the mutations are P-thr, V-val and V-leu in the coding region of EBNA-1 gene, promoters Cp, Fp and Zp of the EBNA-1 gene, and XhoI-loss, 30bp Deletion and Ser 366 Thr of LMP1 gene. The test kit is advantageous in that: the aim of precise prediction of the risk of nasopharyngeal carcinoma in high risk population can be achieved; the main carcinogenic mutations can be well known for the combination of population screening and population intervention for nasopharyngeal carcinoma; and the kit has the advantages of high in sensitivity, fast in test, and low in cost, having broad market prospect.

The present invention relates to a vaccine comprising a particle, said particle comprising (i) at least one Epstein-Barr virus (EBV) structural polypeptide, (ii) at least one EBV lytic polypeptide, (iii) membrane lipids, said particle being devoid of EBV DNA, wherein (a) the B-cell transformation capacity of one or more EBV polypeptides required for B-cell transformation as comprised in said particle is disabled while their immunogenicity is maintained; and/or (b) said particle is devoid of one or more EBV polypeptides required for B-cell transformation. Furthermore, the invention relates to a method for generating a particle, to a cell obtained in the method of the invention, a kit comprising the vaccine or the particle generated according to the method of the invention. Also, the invention relates to the use of the vaccine or the particle generated according to the method of the invention for generating CD8+ cells specific for an EBV antigen.

An isolated protein comprises respective amino acid sequences of each of a plurality of CTL epitopes from two or more different herpesvirus antigens and further comprises an intervening amino acid or amino acid sequence between at least two of said CTL epitopes comprising proteasome liberation amino acids or amino acid sequences and, optionally, Transporter Associated with Antigen Processing recognition motifs. The isolated protein is capable of rapidly expanding human cytotoxic T lymphocytes (CTL) in vitro and eliciting a CTL immune response in vivo upon administration to an animal as an exogenous protein. Typically, the isolated protein comprises no more than twenty (20) CTL epitopes derived from cytomegalovirus and/or Epstein-Barr virus antigens.

The invention provides a peripheral blood-based LCL-NK cell co-culture method, whichcomprises the following steps: preparing and obtaining the PBMC from the peripheral blood, and preparing the LCL cells from the PBMC, wherein the LCL cells are obtained by culturing PBMC (peripheral blood mononuclear cells) in supernate containing EBV (electron barr virus); the EBV supernate is obtained by carrying out culture passage on B958 cells, then carrying out starvation lysis and then separating; and co-culturing the cells in a culture system formed by PBMC, LCL cells, cell factors and a culture solution. According to the culture method provided by the scheme, the purity of a cell product is effectively improved, and the culture efficiency, the NK cell killing property and the like are remarkably improved.

The present invention provides Epstein-Barr virus (EBV)-negative NK cell lines. The NK cell lines of the present invention are useful for screening factors associated with the proliferation and expression functions of NK cells and to discover factors produced by the NK cells. In addition, the cell lines are immortalized despite the fact that they are EBV-negative. Thus, unknown mechanisms of oncogenesis may be elucidated through an understanding of the mechanisms underlying the immortalization of the cell lines of the present invention.

The invention relates to three synthesized EBV (Epstein-Barr Virus) DNA (Deoxyribonucleic Acid) sequences which respectively encodes three consensus amino acid sequences EBNA1 (Epstein-Barr Nuclear Antigen 1), LMP1 (Latent Membrane Protein 1) and LMP2 (Latent Membrane Protein 2). The three sequences are respectively constructed on expression vector plasmids to express corresponding amino acid sequences. The invention further provides different methods for generating anti-corresponding EBV protein antigen immunoreaction by one or more expression plasmids.

The invention discloses a high-throughput sequencing assay method for Epstein-Barr virus (EBV) integration assay. The method utilizes the genome information of the Epstein-Barr virus (EBV) in combination with the second-generation high-throughput sequencing technology to more comprehensively assay the condition of EBV infection of a patient, overcoming the defects of conventional assay methods, such as low accuracy, high false positive and poor repetitiveness. The adoption of gene sequencing can help increasing accuracy, and compared with the classical Sanger sequencing method mostly adopted at present, the assay method has the advantages of higher assay throughput, higher accuracy, lower cost, richer information and the like. With the help of the second-generation high-throughput sequencing technology, the assay method can carry out high-precision assay on the human infection of the Epstein-Barr virus, so that specific treatment can be carried out at the infection stage to reduce theharm of the disease on the human body, and thereby the occurrence of tumor is decreased.